A novel dominant-negative FGFR1 variant causes Hartsfield syndrome by deregulating RAS/ERK1/2 pathway.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
07 2019
Historique:
received: 28 08 2018
accepted: 11 01 2019
revised: 08 01 2019
pubmed: 23 2 2019
medline: 12 6 2020
entrez: 22 2 2019
Statut: ppublish

Résumé

Hartsfield syndrome (HS) is an ultrarare developmental disorder mainly featuring holoprosencephaly and ectrodactyly. It is caused by heterozygous or biallelic variants in FGFR1. Recently, a dominant-negative effect was suggested for FGFR1 variants associated with HS. Here, exome sequencing analysis in a 12-year-old boy with HS disclosed a novel de novo heterozygous variant c.1934C>T in FGFR1 predicted to cause the p.(Ala645Val) amino-acid substitution. In order to evaluate whether the variant, changing a highly conserved residue of the kinase domain, affects FGFR1 function, biochemical studies were employed. We measured the FGFR1 receptor activity in FGF2-treated cell lines exogenously expressing wild-type or Ala645Val FGFR1 by monitoring the activation status of FGF2/FGFR1 downstream pathways. Our analysis highlighted that RAS/ERK1/2 signaling was significantly perturbed in cells expressing mutated FGFR1, in comparison with control cells. We also provided preliminary evidence showing a modulation of the autophagic process in cells expressing mutated FGFR1. This study expands the FGFR1 mutational spectrum associated with HS, provides functional evidence further supporting a dominant-negative effect of this category of FGFR1 variants and offers initial insights on dysregulation of autophagy in HS.

Identifiants

pubmed: 30787447
doi: 10.1038/s41431-019-0350-4
pii: 10.1038/s41431-019-0350-4
pmc: PMC6777633
doi:

Substances chimiques

FGFR1 protein, human EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1 EC 2.7.10.1
MAPK1 protein, human EC 2.7.11.24
MAPK3 protein, human EC 2.7.11.24
Mitogen-Activated Protein Kinase 1 EC 2.7.11.24
Mitogen-Activated Protein Kinase 3 EC 2.7.11.24
ras Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1113-1120

Références

Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66
pubmed: 25772309
Annu Rev Cell Dev Biol. 2011;27:107-32
pubmed: 21801009
Oncogene. 2016 Jun 2;35(22):2852-61
pubmed: 26387545
J Med Genet. 2013 Sep;50(9):585-92
pubmed: 23812909
Eur J Med Genet. 2014 Jul;57(7):345-8
pubmed: 24732674
J Biol Chem. 2000 May 26;275(21):15933-9
pubmed: 10748122
J Dent Res. 2017 Oct;96(11):1339-1345
pubmed: 28825856
Genet Med. 2015 Aug;17(8):651-9
pubmed: 25394172
N Engl J Med. 2013 Feb 14;368(7):651-62
pubmed: 23406030
Nat Genet. 1994 Nov;8(3):269-74
pubmed: 7874169
Circ Res. 2012 Feb 17;110(4):e29-39
pubmed: 22207710
Methods Mol Biol. 2000;132:365-86
pubmed: 10547847
Am J Med Genet A. 2016 Aug;170(8):2222-5
pubmed: 27170295
Hum Genome Var. 2016 Oct 13;3:16034
pubmed: 27790375
Am J Hum Genet. 2016 Mar 3;98(3):579-587
pubmed: 26942290
Clin Endocrinol (Oxf). 2015 Jan;82(1):122-6
pubmed: 24841555
J Exp Clin Cancer Res. 2017 May 30;36(1):72
pubmed: 28558758
PLoS One. 2012;7(10):e46642
pubmed: 23118857
Hum Mol Genet. 2016 May 15;25(10):1912-1922
pubmed: 26931467
Am J Hum Genet. 2005 Feb;76(2):361-7
pubmed: 15625620
Nature. 2015 Dec 10;528(7581):272-5
pubmed: 26595272
Am J Med Genet A. 2014 Sep;164A(9):2356-9
pubmed: 24888332
Gene. 2017 Jul 20;621:1-4
pubmed: 28411082
Expert Rev Endocrinol Metab. 2013 Jul;8(4):391-402
pubmed: 25400686
Am J Med Genet A. 2016 Dec;170(12):3359
pubmed: 27604603
Int J Pediatr Otorhinolaryngol. 2017 Jul;98:4-8
pubmed: 28583501
Genes Dis. 2014 Dec 1;1(2):199-213
pubmed: 25679016
Nat Genet. 2003 Apr;33(4):463-5
pubmed: 12627230
J Biol Chem. 2018 Jun 8;293(23):8761-8774
pubmed: 29691281

Auteurs

Pietro Palumbo (P)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, FG, Italy.

Antonio Petracca (A)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, FG, Italy.

Roberto Maggi (R)

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Studi di Milano, Italy.

Tommaso Biagini (T)

Fondazione IRCCS Casa Sollievo della Sofferenza, Unit of Bioinformatics, San Giovanni Rotondo, FG, Italy.

Grazia Nardella (G)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, FG, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Michele Carmine Sacco (MC)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Pediatrics, San Giovanni Rotondo, FG, Italy.

Elia Di Schiavi (E)

Institute of Biosciences and Bioresources, National Research Council (CNR), Naples, Italy.

Massimo Carella (M)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, FG, Italy.

Lucia Micale (L)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, FG, Italy. l.micale@operapadrepio.it.

Marco Castori (M)

Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, FG, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH